Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.

Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow

Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call Transcript

Shares of Bristol Myers Squibb rose early Wednesday, after the company reported earnings that just beat Wall Street expectations.

Bristol Myers Squibb Stock Rises After Modest Earnings Beat

Bristol Myers (BMY) delivered earnings and revenue surprises of 2.66% and 4.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb & Co (NYSE: BMY) posted Q2 revenues of $11.7 billion, an increase of 16%, or 13%, when adjusted for foreign exchange, slightly above the consensus estimate of $11.3 billion.  Sales in the same period a year ago were negatively impacted by approximately $350 million of COVID-19-related channel inventory work downs.

Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance

Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 18.40% over the past year to $1.93, which beat the estimate of $1.91.

Recap: Bristol-Myers Squibb Q2 Earnings

Bristol Myers Squibb Co. said Wednesday it swung to a profit of $1.055 billion, or 47 cents a share, in the second quarter, after a loss of $85 million, or 4 cents a share, in the year-earlier period. Adjusted per-share earnings came to $1.93, ahead of the $1.89 FactSet consensus.

Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth

Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

Bristol Myers sees return to growth for Opdivo, tops estimates

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

A combination of solid earnings and a decent-size dividend make the drugmakers shares a solid bet.

Why It's Hard to Go Wrong With Bristol Myers Stock

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

British American Tobacco

Enterprise Products Partners

Altria

Orange

Reinsurance Group of America

Unum

In today's market, finding good companies to invest in has become a hard thing to do, downright impossible in some sectors. Nonetheless, there do exist a few sectors and opportunities that warrant mentioning.

7 Companies With 2.6-7.5% Yield And 20%+ Annual Upside

Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who previously received Bayer AG's (OTC: BAYRY) standard-of-care Nexavar. The decision came about three months after an independent FDA advisory committee voted 5-4 to remove the Opdivo accelerated approval, which the company scored back in 2017 based on tumor shrinkage data.

Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer

Amazon

General Motors

Riding the Oracle of Omaha's coattails is a moneymaking proposition.

3 Warren Buffett Stocks That Are Screaming Summer Buys

Bristol Myers Squibb is one of the largest pharmaceutical companies backed by a pristine Balance Sheet. Shares of BMY are vastly undervalued and present a tremendous opportunity for long-term investors.

Bristol Myers Squibb: An Undervalued Dividend Stock With Growth Potential

AbbVie

Amgen

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Johnson & Johnson

Merck

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Baxter

Cigna

Cisco Systems

Chevron

D.R. Horton

Gaming and Leisure Properties

Barrick Gold

Intel

Lowe's

PepsiCo

Raytheon Technologies

Exxon Mobil

Kiplinger Investing publishes opportune buy-lists for investors online. Two billionaire stock-lists by Dan Burrows included 50 published 12/8/20, with 30 more out June 1, 2021. Seventeen were duplicated, leaving 63. 41 of these 63 billionaire-held stocks pay dividends. As of 7/20/21, the top-ten ranged 2.52%-6.22% by annual yield and ranged 23.13%-52.70% per broker-estimated price-target upsides.

Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys

They may not remain cheap for much longer.

2 Dirt Cheap Dividend Stocks You Can Buy Right Now

AGNC Investment

CrowdStrike

Green Thumb Industries Inc.

Home Depot

NextEra Energy

U.S. Bancorp

Big market declines are the perfect opportunity for long-term investors to put their capital to work.

7 Stocks to Buy Hand Over Fist if the Stock Market Crashes

Kraft Heinz

The stocks come pre-vetted by the best in the business.

Got $5,000? Here Are 2 Cheap Warren Buffett Stocks to Buy

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

Bristol Myers Squibb (BMY) closed the most recent trading day at $67.30, moving -0.19% from the previous trading session.

Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know

Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints of the trial.  The trial assessed Opdivo plus Yervoy combination to Extreme regimen (cetuximab, cisplatin/carboplatin, and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial

Bristol Myers Squibb Co. said Friday a late-stage study of a treatment for head and neck cancer failed to meet its main goals. The Phase 3 trial sought to compare Opdivo plus Yervoy to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Provides Update on CheckMate -651

Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck

News for Bristol-Myers Stock (BMY)